As advised via PHARMAC Tender Results of 31 May 2019 there is to be a change in the listing and future sole supply of Amoxicillin Capsules.

New listing from 1 November 2019

Alphamox Cap 250 mg 500 Blister Pack                                                                             Pharmacode TBA                                     Schedule price $22.50

Alphamox Cap 500 mg 500 Blister Pack                                                                             Pharmacode TBA                                      Schedule price $36.98

Incumbent brand

Amoxi-Apo Tab 250 mg 500 bottle pack                                                                            Pharmacode 383015                      Schedule price $14.97

Amoxi-Apo Tab 500 mg 500 bottle pack                                                                            Pharmacode 2499738                    Schedule price $16.75

HSS (Hospital Supply Status) & CSS (Community Supply Status) commences 1 April 2020.

Brand switch fee for Community Pharmacy not notified with tender results.

As of the date of this notification ProPharma / PWR cannot accept Amoxil-Apo for credit under any circumstances.

From 1 November 2019 community pharmacies dispensing Amoxicillin Capsules will need to support patients changing to the new brand and manage stock during the transition.

We would recommend you continue to purchase the incumbent and we will change automatically as existing stocks are exhausted.

You MUST manage your stock to avoid being caught with stock at the time sole supply commences 1 April 2020. Failure to do so may prove very costly.

Once again we need your support to ensure stock in the supply chain moves through, to effectively ensure no losses are incurred by – supplier, wholesaler and pharmacy.

ProPharma / PWR will make a commercial decision in relation to stock holding which will potentially mean a change for pharmacy and patient. Unfortunately with the PHARMAC decision to have both new and incumbent products listed and fully funded until the commencement of the sole supply 1 April 2020 we need to act in the best interest of the company, pharmacy and patient. The patient will need to change, however wholesalers and pharmacy do not need to experience potential losses during the transition period.

Together we can make this a seamless and painless transition.

We thank you in anticipation of your ongoing support.

About The Author

Close